Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.
List view / Grid view
acute myeloid leukaemia (AML)
Filter the results
A clinical study is to be launched after researchers found that a common and inexpensive drug may be used to counteract treatment resistance in patients with AML.
A possible new avenue for treatment of Acute Myeloid Leukaemia (AML) has opened up after US scientists pinpoint how the cancer spreads using excessive amounts of vitamin B6.
A pioneering team of scientists from Rice University has discovered that a particular combination of chemotherapeutics, including mitocans that target mitochondria, form a powerful treatment for acute myeloid leukaemia patients.
Researchers have found a molecule, which when deleted, increases leukaemia sensitivity to natural killer cells and is a drug target.
The epigenetic protein, EZH2, was found to delay the development of acute myeloid leukemia (AML) but also switches sides to maintain tumour growth...
New study uses CRISPR/Cas9 to make CD33 CAR T cells cancer-specific...
Researchers have discovered that a signalling protein elevated in patients with AML plays a much wider role in the disease than previously thought...